Click the image to enlarge
Johnson & Johnson is trading amid heightened regulatory and litigation sensitivity following a voluntary recall of its Cerepak Detachable Coil Systems.
While RBC upgraded its price target to $255, citing oncology ambitions and balance-sheet strength, legal uncertainty linked to the Daubert ruling remains a persistent overhang.
2025 revenue reached $94.2B (+6% YoY), with 2026 guidance at $100.5B, signalling steady momentum. Management’s long-term oncology target of $50B in annual revenue reinforces strategic credibility, but near-term price action is dominated by regulatory headlines.
Bottom Line: Strong fundamentals and oncology growth ambitions are offset by ongoing litigation and recall-driven uncertainty.
#dailyanalysis #jnj #JohnsonandJohnson #veldoratrading #financialreport #rbc
Add comment
Comments